Perry M. Novak

Discovery of Aryl Aminoquinazoline Pyridones as Potent, Selective, and Orally Efficacious Inhibitors of Receptor Tyrosine Kinase c-Kit

Inhibition of c-Kit has the potential to treat mast cell associated fibrotic diseases. We report the discovery of several aminoquinazoline pyridones that are potent inhibitors of c-Kit with greater than 200-fold selectivity against KDR, p38, Lck, and Src. In vivo efficacy of pyridone 16 by dose-dependent inhibition of histamine release was demonstrated in a rodent pharmacodynamic model of mast cell activation.

New preparations of the N-methyl-D-aspartate receptor antagonist, 4-(3-phosphonopropyl)-2-piperazinecarboxylic acid (CPP)

Two new methods to ensure selective alkylation of the N4 of 2-piperazinecarboxylic acid to give 4-(3-phosphonopropyl)-2-piperazinecarboxylic acid (CPP, 1) are reported. CPP can be conveniently prepared using a copper chelate to selectively protect the N1 position during alkylation. A second procedure uses methyl-4-BOC-1-CBZ-2-piperazinecarboxylate 5 as a versatile intermediate, which was further elaborated to CPP.